Business Context and Reporting Period
This Form 8-K filing by Gain Therapeutics, Inc. (GANX) was submitted on July 11, 2024, regarding a listing deficiency notice received from The Nasdaq Stock Market on June 11, 2024. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The primary financial metric disclosed is the Market Value of Listed Securities (MVLS), which fell below the required minimum of $50 million for the period between May 8, 2024, and July 10, 2024.
Material Changes
The material change reported is the failure to satisfy the Nasdaq Listing Rule 5450(b)(2)(A) regarding the MVLS Requirement. The Company's MVLS remained below the $50 million threshold for the specified period, triggering a deficiency notice.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has 180 calendar days from the notice date, until January 7, 2025, to regain compliance.
- Compliance Criteria: To regain compliance, the MVLS must close at $50 million or more for a minimum of ten consecutive business days during the compliance period.
- Consequences of Non-Compliance: If compliance is not achieved by the deadline, Nasdaq will issue a delisting notice. The Company may appeal this determination or consider transferring to The Nasdaq Capital Market.
- Management Stance: Management intends to actively monitor the MVLS and take all reasonable measures to regain compliance, though there is no assurance of success.
- Risks: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks outlined in the Company's 2023 Form 10-K.
Investor Verification Checklist
- Verify the current Market Value of Listed Securities (MVLS) to assess proximity to the $50 million threshold.
- Monitor the stock price for ten consecutive business days to determine if the compliance criteria are being met.
- Review the Company's 2023 Form 10-K for detailed risk factors related to delisting and capitalization.
- Watch for future announcements regarding an appeal of a potential delisting or an application to transfer to The Nasdaq Capital Market.